Luye Pharma Group Ltd.
SHSC:2186 주식 보고서
Luye Pharma Group 대차 대조표 상태 Luye Pharma Group 의 총 주주 지분은 CN¥14.1B 이고 총 부채는 CN¥9.4B, 이는 부채 대 자기자본 비율을 66.6% 로 가져옵니다. 총자산과 총부채는 각각 CN¥27.2B 및 CN¥13.1B 입니다. Luye Pharma Group 의 EBIT는 CN¥1.3B 이며 이자보상배율은 2.9 입니다. CN¥6.5B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보 이자 보상 비율 2.9x 현금 CN¥6.48b 주식 CN¥14.08b 총 부채 CN¥13.11b 총 자산 CN¥27.20b
최근 재무 상태 업데이트
모든 업데이트 표시
First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023) Oct 02
First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023) Aug 30
Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder Jul 29 Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion. Jul 24
Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China Jul 04
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China Jun 13
Now 20% overvalued Apr 25
Now 23% overvalued Apr 08
Full year 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.17 in FY 2022) Mar 29
Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024 Mar 28
Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 15
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao Mar 09
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610 Mar 04
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States Feb 02
Now 20% undervalued after recent price drop Jan 26
Investor sentiment deteriorates as stock falls 17% Jan 08
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong Dec 12
Luye Pharma Group Ltd. Announces Board Changes Dec 06
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder Oct 11
First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022) Oct 01
Investor sentiment improves as stock rises 16% Sep 14
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio Sep 09
First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022) Aug 31
Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin Aug 22 Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States
Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China Jul 07
Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy Jul 06
Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan Jun 09
Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China Jun 08
Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director May 26
Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.039 loss in FY 2021) Mar 30
Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022) Jan 31
FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder Jan 16
Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010) Dec 29
Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014 Nov 30
Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate Nov 22
Less than half of directors are independent Nov 16
Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA Nov 04 Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding Sep 15
First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021) Aug 31
Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022 Aug 18
Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China Aug 16
Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine Jul 20
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan Jul 19
Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China Jul 15
Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting Jun 09
Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting Jun 07
Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022 May 18
Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China May 12
Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020) May 02
Less than half of directors are independent Apr 27
Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020) Apr 01
Investor sentiment improved over the past week Mar 22
Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection Mar 06
Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in China Feb 26
Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United States Jan 20
Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) Dec 30
Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets Dec 23
Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in China Dec 15
First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020) Oct 01
Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Dulaglutide Injection (BA5101) in China Sep 29
Luye Pharma Group Ltd.'s New Drug Rivastigmine Multi-Day Transdermal Patch Receives Marketing Authorization from the Medicines & Healthcare Products Regulatory Agency in the United Kingdom Sep 24
Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia Sep 20
First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020) Sep 02
Luye Pharma Group Ltd. Announces Clinical Trial Application Submitted in the U.S. for the Group's U0027s New Drug LY03015 Aug 04
Shandong Boan Biotechnology Co. Ltd. Submits Investigational New Drug Application for Its New Drug LY-CovMab to the Food and Drug Administration of the U.S Jun 16
Luye Pharma Group Ltd. Announces Acceptance of Marketing Authorization Application for Class 1 New Drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) in China Jun 11
Investor sentiment improved over the past week May 24
Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for its New Drug LY09606 in China May 14 Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Nivolumab Injection in China
Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.44 in FY 2019) May 02
Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.46 in FY 2019) Apr 02
Luye Pharma Group Ltd. Announces Enrolment of Subjects in Phase I Clinical Trial in the People's Republic of China Commenced in Relation to the Group's Class 1 New Drug LPM3480392 Injection Mar 19
Luye Pharma Group Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 17
Centre for Drug Evaluation of the National Medical Products Administration in the People's Republic of China Accepts Luye Pharma Group Ltd.'s Application for its New Drug LY09606 Mar 09 Luye Pharma Group Ltd. Announces Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Ophthalmic Injection of Shandong Boan Biotechnology Co. Ltd. Completes the First Patient Dosing in Phase III Clinical Trial in China
Investor sentiment improved over the past week Feb 01
New 90-day high: HK$5.90 Feb 01
Luye Pharma Group Ltd. Announces Completion of Enrollment of Subjects in Phase I Clinical Trial for Neutralizing Antibody Against SARS-CoV--2 in China Jan 20
Luye Pharma Group Ltd. Announces Marketing Registration of Risperidone Microspheres for Injection Approved by NMPA Jan 17
Luye Pharma Group Ltd. Announces Rotigotine Extended-Release Microspheres for Injection (Ly03003) Completed Phase I Clinical Trial in Japan Jan 16
Luye Pharma Group Ltd. Updates on LY03009 Commenced Phase I Clinical Trial in Australia Jan 06
New 90-day low: HK$3.61 Dec 31
Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial of Class 1 New Drug Product, the Extended Release Tablets Dec 25
Luye Pharma Group Ltd. Announces Commencement of LY03010 Pivotal Study in the U.S Dec 23
New 90-day low: HK$3.87 Dec 10
Market pulls back on stock over the past week Dec 10
Luye Pharma Group Ltd. Announces Executive Changes Dec 02
Luye Pharma and Distriphil Enters Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness Nov 27
재무 상태 분석
단기부채: 2186 의 단기 자산 ( CN¥12.5B )이 단기 부채 ( CN¥9.8B ).
장기 부채: 2186 의 단기 자산( CN¥12.5B )이 장기 부채 ( CN¥3.3B ).
부채 대 자본 내역 및 분석
부채 수준: 2186 의 순부채 대 자기자본 비율 ( 20.6% )은 satisfactory 로 간주됩니다.
부채 감소: 2186 의 부채 대 자기자본 비율은 지난 5년간 70.7% 에서 66.6% 로 감소했습니다.
부채 범위: 2186 의 부채는 영업 현금 흐름 ( 5.4% )에 의해 잘 갚지 않음 입니다.
이자 보장: 2186 의 부채에 대한 이자 지급 은 EBIT ( 2.9 x 적용 범위)만큼 잘 덮이지 않음 입니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}